Ocular Therapeutix Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Pravin Dugel

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	1.3yrs
Board average tenure	4.9yrs

Recent management updates

Recent updates

CEO

Pravin Dugel (59 yo)

less than a year

Tenure

Dr. Pravin U. Dugel, M. D. has been Executive Chairman of Ocular Therapeutix, Inc. since February 2024 and also serves as its Chief Executive Officer and President since April 15, 2024. He served as Presid...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Donald Notman	Chief Financial Officer	6.7yrs	US$1.34m	0.051% $ 426.2k
Jeffrey Heier	Chief Scientific Officer	less than a year	US$329.90k	0.031% $ 261.4k
Rabia Ozden	Chief Medical Officer	3.3yrs	US$1.48m	0.019% $ 162.2k
Pravin Dugel	Executive Chairman	less than a year	no data	no data
Karen-Leigh Edwards	Chief Operations Officer	less than a year	no data	no data
Peter Jarrett	Chief Technology Officer	no data	no data	no data
William Slattery	Vice President of Investor Relations	no data	no data	no data
Philip Strassburger	General Counsel	3.7yrs	US$2.41m	no data
William Ransone	Vice President of Global Sales & Marketing	no data	no data	no data
Tracy Smith	Vice President of Human Resources	3.7yrs	no data	no data
Steve Meyers	Chief Commercial Officer	1.3yrs	no data	no data
Peter Kaiser	Chief Development Officer	less than a year	no data	no data

1.3yrs

Average Tenure

62yo

Average Age

Experienced Management: 0OT's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Pravin Dugel	Executive Chairman	less than a year	no data	no data
Charles Warden	Lead Independent Director	16.3yrs	US$303.61k	0.031% $ 264.2k
Merilee Raines	Independent Director	2.7yrs	US$263.61k	0.0058% $ 48.7k
Richard Lindstrom	Independent Director	11.5yrs	US$261.11k	0.090% $ 756.3k
Adrienne Graves	Independent Director	less than a year	US$397.89k	no data
Leslie Williams	Independent Director	5.2yrs	US$261.11k	0.0087% $ 73.2k
Seung Hong	Independent Director	4.9yrs	US$248.61k	0.0058% $ 48.7k

4.9yrs

Average Tenure

65yo

Average Age

Experienced Board: 0OT's board of directors are considered experienced (4.9 years average tenure).

Ocular Therapeutix Management

Management criteria checks 1/4

Key information

Recent management updates

Ocular Therapeutix, Inc., Annual General Meeting, Jun 12, 2024

Ocular Therapeutix, Inc. Announces CEO Changes

Ocular Therapeutix, Inc. Announces Management Changes

Ocular Therapeutix, Inc. Appoints Steve Meyers as Chief Commercial Officer

President recently sold €84k worth of stock

Ocular Therapeutix™ Announces Appointment of Adrienne L. Graves as New Board Member

Recent updates

Ocular Therapeutix, Inc. to Report Q1, 2024 Results on May 07, 2024

Ocular Therapeutix, Inc., Annual General Meeting, Jun 12, 2024

Ocular Therapeutix, Inc. Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy

Ocular Therapeutix, Inc. Announces CEO Changes

Ocular Therapeutix, Inc. Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting

New major risk - Shareholder dilution

Full year 2023 earnings released: US$1.01 loss per share (vs US$0.92 loss in FY 2022)

Ocular Therapeutix, Inc. to Report Q4, 2023 Results on Mar 11, 2024

Ocular Therapeutix, Inc. Announces Management Changes

AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA

Ocular Therapeutix, Inc. Appoints Steve Meyers as Chief Commercial Officer

President recently sold €84k worth of stock

Ocular Therapeutix Announces FDA Agreement to Amend Special Protocol Assessment (Spa) for Pivotal Clinical Trial of Axpaxli in Wet AMD

Ocular Therapeutix, Inc. has completed a Follow-on Equity Offering in the amount of $100.1 million.

Ocular Therapeutix, Inc. has completed a Follow-on Equity Offering in the amount of $100.1 million.

New minor risk - Profitability

Ocular Therapeutix, Inc. Provides Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings released: US$0.006 loss per share (vs US$0.31 loss in 3Q 2022)

Ocular Therapeutix Receives FDA Agreement Under Special Protocol Assessment (SPA) for its First Pivotal Clinical Trial of OTX-TKI in Wet AMD

AffaMed Therapeutics Announces Positive Top-Line Results from Real-World Study in China Evaluating the Safety and Efficacy of DEXTENZA® in Patients after Cataract Surgery

Ocular Therapeutix, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Ocular Therapeutix, Inc. Announces Initiation of Its First Pivotal Clinical Trial of OTX-TKI in Wet AMD

Ocular Therapeutix, Inc. Submits Request for Special Protocol Assessment to the U.S. Food and Drug Administration

New minor risk - Financial position

Second quarter 2023 earnings released: US$0.27 loss per share (vs US$0.24 loss in 2Q 2022)

Ocular Therapeutix, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Ocular Therapeutix™ Announces Appointment of Adrienne L. Graves as New Board Member

New major risk - Share price stability

Ocular Therapeutix, Inc. Completes Enrollment of the Helios Clinical Trial of OTX-TKI for the Treatment of Diabetic Retinopathy

Ocular Therapeutix, Inc. Present 12-Month Top-Line Data from U.S.-Based Phase 1 Clinical Trial of OTX-TKI

Ocular Therapeutix, Inc. Provides Earnings Guidance for the Year 2023

First quarter 2023 earnings released: US$0.39 loss per share (vs US$0.16 loss in 1Q 2022)

Full year 2022 earnings released: US$0.92 loss per share (vs US$0.086 loss in FY 2021)

Ocular Therapeutix™ Announces Interim 10-Month Data from the Ongoing U.S. Phase 1 Clinical Trial Evaluating OTX-TKI for the Treatment of Wet AMD

Insufficient new directors

Third quarter 2022 earnings released: US$0.31 loss per share (vs US$0.035 profit in 3Q 2021)

Ocular Therapeutix, Inc. Provides Earnings Guidance for the Fiscal Year 2022

Ocular Therapeutix, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Ocular Therapeutix, Inc. Announces Interim 7-month Data from U.S. Phase 1 Clinical Trial of OTX-TKI for the Treatment of Wet AMD

Ocular Therapeutix, Inc. Provides Revenue Guidance for the Full Year 2022

Second quarter 2022 earnings released: US$0.24 loss per share (vs US$0.11 loss in 2Q 2021)

Insufficient new directors

Ocular Therapeutix, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Insufficient new directors

Ocular Therapeutix, Inc. Announces Executive Changes

Ocular Therapeutix, Inc. Announces Executive Changes

First quarter 2022 earnings released: US$0.16 loss per share (vs US$0.041 profit in 1Q 2021)

Ocular Therapeutix, Inc. Provides Earnings Guidance for the Full Year 2022

Ocular Therapeutix, Inc., Annual General Meeting, Jun 16, 2022

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Ocular Therapeutix, Inc. to Report Q4, 2021 Results on Feb 28, 2022

Ocular Therapeutix, Inc. Announces Resignation of Bruce A. Peacock as Member of the Board of Directors

Third quarter 2021 earnings released: EPS US$0.035 (vs US$0.19 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.11 loss per share (vs US$0.64 loss in 2Q 2020)

Ocular Therapeutix, Inc. Provides Earnings Guidance for the Second Quarter Ended June 30, 2021

Independent Director recently sold €117k worth of stock

First quarter 2021 earnings released: EPS US$0.041 (vs US$0.41 loss in 1Q 2020)

Ocular Therapeutix Fulfills Post-Marketing Approval Requirements for ReSure Sealant

Chief Operating Officer has left the company

Ocular Therapeutix™ To Present Pre-Clinical and Clinical Data at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Full year 2020 earnings released: US$2.56 loss per share (vs US$1.91 loss in FY 2019)

Revenue misses expectations

Ocular Therapeutix™ Announces FDA Acceptance of Supplemental New Drug Application for DEXTENZA® (dexamethasone ophthalmic insert) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis

Ocular Therapeutix, Inc. Announces First Patient Dosed in Phase 2 Clinical Trial of OTX-DED for the Short-Term Treatment of the Signs and Symptoms of Dry Eye Disease

Ocular Therapeutix, Inc. to Report Q4, 2020 Results on Mar 11, 2021

New 90-day high: €19.30

Ocular Therapeutix, Inc. Presents Interim Topline Data from the Phase 1 Clinical Trial of OTX-TIC in Patients with Primary Open Angle Glaucoma or Ocular Hypertension

New 90-day high: €19.10

Ocular Therapeutix, Inc. Announces Executive Changes